Psoriasis/Psoriatic Arthritis Patients' Long-term Treatment Patterns and Adherence to Systemic Treatments Monitoring Recommendations

被引:4
|
作者
Krantz, Asa [1 ,2 ]
Carrero, Juan Jesus [3 ,4 ]
Yang, Yuanhang [3 ]
Schalin, Lovisa [5 ]
Lysell, Josefin [1 ,2 ]
Mazhar, Faizan [3 ,6 ]
机构
[1] Karolinska Univ Hosp, Danderyd Hosp, Unit Dermatol, Stockholm, Sweden
[2] Danderyd Hosp, Karolinska Inst, Dept Med Solna, Dermatol & Venereol Sect, Stockholm, Sweden
[3] Danderyd Hosp, Karolinska Inst, Dept Med Epidemiol & Biostat, Stockholm, Sweden
[4] Danderyd Hosp, Karolinska Inst, Dept Clin Sci, Div Nephrol, Stockholm, Sweden
[5] Amgen Inc, Solnam, Sweden
[6] Karolinska Inst, Dept Med Epidemiol & Biostat MEB, Nobels Vag 12A,Box 281, Stockholm, SE, Brazil
基金
瑞典研究理事会;
关键词
adherence; persistence; treatment patterns; guide; PSORIATIC-ARTHRITIS; BIOLOGICS; THERAPIES; TRENDS;
D O I
10.2340/actadv.v103.6505
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Limited information exists regarding treatment of patients with psoriasis/psoriatic arthritis in primary care. The aim of this study is to assess treatment patterns, adherence, persistence, and compliance in newly diagnosed patients with psoriasis/psoriatic arthritis from 2012 to 2018 in Stockholm, Sweden. In addition, laboratory monitoring before initiation of treatment and at recommended intervals was quantified for patients prescribed methotrexate or biologics. A total of 51,639 individuals were included, with 39% initiating treatment with topical corticosteroids and < 5% receiving systemic treatment within 6 months post-diagnosis. During a median (interquartile range) follow-up of 7 (4-8) years, 18% of patients received systemic treatments at some point. Overall, 5-year persistence rates were 32%, 45% and 19% for methotrexate, biologics, and other systemic treatments, respectively. Pre-initiation laboratory tests, as recommended by guidelines, were performed in approximately 70% and 62% of methotrexate and biologics users, respectively. Follow-up monitoring at recommended time intervals occurred in 14-20% and 31-33% of patients prescribed methotrexate and biologics, respectively. These findings highlight gaps in the pharmacological care of patients with psoriasis/ psoriatic arthritis, including suboptimal adherence/ persistence and inadequate laboratory monitoring.
引用
收藏
页数:8
相关论文
共 50 条
  • [31] Treatment patterns among patients with rheumatic disease (rheumatoid arthritis (RA), ankylosing spondylitis (AS), psoriatic arthritis (PsA) and undifferentiated arthritis (UnA)) treated with subcutaneous TNF inhibitors
    Tymms, Kathleen
    Littlejohn, Geoff
    Griffiths, Hedley
    de Jager, Julien
    Bird, Paul
    Joshua, Fred
    Nash, Peter
    Handel, Malcolm
    McManus, Hamish
    Butcher, Belinda E.
    Youssef, Peter
    CLINICAL RHEUMATOLOGY, 2018, 37 (06) : 1617 - 1623
  • [32] Systemic treatment of psoriasis and psoriatic arthritis in the United States: a cross-sectional study
    Steuer, Alexa B.
    Wang, Jason F.
    Feng, Hao
    Cohen, Jeffrey M.
    JOURNAL OF DERMATOLOGICAL TREATMENT, 2022, 33 (02) : 1193 - 1194
  • [33] Effect of Psoriatic Arthritis on Treatment Response in Patients With Moderate to Severe Psoriasis
    Greb, Jacqueline E.
    Garber, Caren
    Gottlieb, Alice B.
    JOURNAL OF DRUGS IN DERMATOLOGY, 2016, 15 (08) : 917 - 922
  • [34] Factors associated with long-term retention of treatment with golimumab in rheumatoid arthritis, axial spondyloarthritis, and psoriatic arthritis: an analysis of the Spanish BIOBADASER registry
    Pombo-Suarez, Manuel
    Sanchez-Piedra, Carlos
    Garcia-Magallon, Blanca
    Perez-Gomez, Ana
    Manrique-Arija, Sara
    Martin-Domenech, Raquel
    Colazo, Maria
    Campos, Cristina
    Campos, Jose
    del Pino-Montes, Javier
    Arteaga, Maria J.
    Cea-Calvo, Luis
    Diaz-Gonzalez, Federico
    Gomez-Reino, Juan J.
    CLINICAL RHEUMATOLOGY, 2021, 40 (10) : 3979 - 3988
  • [35] Efalizumab. Long-term treatment of psoriasis
    Prinz, JC
    HAUTARZT, 2005, 56 (09): : 812 - +
  • [36] Treatment patterns, adherence, and persistence among psoriasis patients treated with biologics in a real-world setting, overall and by disease severity
    Murage, Mwangi J.
    Anderson, Amanda
    Casso, Deborah
    Oliveria, Susan A.
    Ojeh, Clement K.
    Muram, Talia M.
    Merola, Joseph F.
    Zbrozek, Art
    Araujo, Andre B.
    JOURNAL OF DERMATOLOGICAL TREATMENT, 2019, 30 (02) : 141 - 149
  • [37] Drug utilization patterns and adherence in patients on systemic medications for the treatment of psoriasis: A retrospective, comparative cohort study
    Dommasch, Erica D.
    Lee, Moa P.
    Joyce, Cara J.
    Garry, Elizabeth M.
    Gagne, Joshua J.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2018, 79 (06) : 1061 - +
  • [38] Long-term adherence to statin treatment in diabetes
    Donnelly, L. A.
    Doney, A. S. F.
    Morris, A. D.
    Palmer, C. N. A.
    Donnan, P. T.
    DIABETIC MEDICINE, 2008, 25 (07) : 850 - 855
  • [39] Long-Term Treatment Patterns Among Patients With Psoriasis Treated With Ixekizumab or Adalimumab: A Real-World Study
    Blauvelt, Andrew
    Shi, Nianwen
    Murage, Mwangi J.
    Ridenour, Terri Lynn
    Lew, Carolyn R.
    Somani, Najwa
    Zhu, Baojin
    Zimmerman, Nicole M.
    Kern, Scott A.
    Burge, Russel T.
    JOURNAL OF DRUGS IN DERMATOLOGY, 2022, 21 (04) : 399 - 407
  • [40] Apremilast Adherence and Persistence in Patients with Psoriasis and Psoriatic Arthritis in the Telehealth Setting Versus the In-person Setting During the COVID-19 Pandemic
    Ashis K. Das
    Eunice Chang
    Caleb Paydar
    Michael S. Broder
    Kate K. Orroth
    Myriam Cordey
    Dermatology and Therapy, 2023, 13 : 1973 - 1984